The Story

Harnessing Nature

Alpha Fetoprotein (AFP) is a human protein produced by the embryo during fetal development
and serves two critical functions:

  1. Normalizes immune system responses so the mother’s immune cells don’t attack the embryo; and
  2. Picks up nutrients from the mother and delivers them to the embryo.

AFP enters maternal bloodstream and picks hydrophobic substances, needed by rapidly growing embryo. AFP circulates until
it finds receptors which are present on all embryonic cells. It then binds to the receptor and is transported
into cell where the payload is released. After birth, the production of AFP stops and the receptors
disappear.

Learn More

Immunomodulation
Platform
ACT-101

Immunomodulation Platform

ACT-101 is recombinant human alpha-fetoprotein — the only recombinant human AFP in clinical development. AFP is the protein the fetus uses to maintain immune tolerance during pregnancy; ACT-101 delivers that biology as a manufactured biologic, expressed in E. coli. In Phase I/II studies conducted by our licensor, more than 370 patients were dosed with no serious adverse events attributable to ACT-101 and no neutralizing antibodies. ACT-101 is in development for autoimmune diseases in which restoring immune tolerance is the therapeutic goal, including ulcerative colitis and myasthenia gravis (FDA orphan drug designation).

Learn More
Pre-Clinical MG Studies
Pre-Clinical IBD Studies

Targeted Immuno-Oncology
Platform
ACT-903

Targeted Immuno-Oncology Platform

Most cancer cells like embryonic cells express AFP receptors while healthy cells do not.

By attaching a chemotherapy payload to AFP we can selectively deliver toxins to cancer cells bypassing normal cells. This
results in increased efficacy and a significant reduction in toxicity.

Learn More
Pre-Clinical IO Studies

Radiopharmaceuticals Platform

Cancer imaging and therapeutic development work is underway with Sam Sadeghi’s lab at McMaster University, previous work with 3D imaging, Charles River Laboratories,  Centre for Probe Development and Commercialization –  AtomVie for 89Zr-ACT-101 (diagnostic) and later using 177Lu-ACT-101 (therapeutic).